Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients…

2024 ASH Annual Meeting Insights Hub

M. Shadman

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

ASH 2024 Insights: De-Escalated PTCy & Ruxolitinib for GVHD Prophyla…

2024 ASH Annual Meeting Insights Hub

S. Abedin

Making Sense of 1L Treatment Options in MCL

SOHO Brazil 2024

T. Phillips

CLL and MCL: Experts Discuss the Use of Pirtobrutinib

MyCancerHaven

R. Vij, G. Shouse

Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN…

Fox Chase Cancer Center

S. Nakhoda

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong